Immunotherapeutic agent
Inventors
Brunet, Laura Rosa • Lowry, Christopher A.
Assignees
Immodulon Therapeutics Ltd • University of Colorado Colorado Springs
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10736864-B2
Publication Date
2020-08-11
Expiration Date
Abstract
Compounds for use in the treatment of sepsis and/or the prevention or treatment of post-sepsis syndrome.
Core Innovation
The invention relates to immunotherapeutic and anti-inflammatory lipid compounds for sepsis and to the prevention and treatment of post-sepsis syndrome (PSS). The compounds are described as esters of 1,2,3-propanetriol with C11–C24 fatty acids having a double bond at the C10–C11 position, including 10(Z)-hexadecenoic acid.
The disclosure states that the lipid compounds inhibit LPS-stimulated IL-6 secretion from macrophages. It also states that the compounds downregulate proinflammatory cytokine and chemokine mRNA, as supported by RNAseq analysis results.
The disclosure further states that the compounds activate PPAR signaling and provides supporting in vitro and in vivo data. It also describes administering 10(Z)-hexadecenoic acid to a patient in need to treat sepsis and/or prevent or treat PSS.
Claims Coverage
The provided material includes one independent claim covering a method of treating sepsis and/or preventing or treating post-sepsis syndrome by administering 10(Z)-hexadecenoic acid. Dependent coverage refines the administration route with intravenous injection or an intratracheal route.
Treating sepsis and/or post-sepsis syndrome with 10(Z)-hexadecenoic acid
A method of treating sepsis and/or preventing or treating post-sepsis syndrome comprising administering a therapeutically effective amount of 10(Z)-hexadecenoic acid to a patient in need of such treatment.
Intravenous injection administration route
The method specifies administering 10(Z)-hexadecenoic acid via intravenous injection.
Intratracheal administration route
The method specifies administering the fatty acid molecule using the intratracheal route.
Overall, the claim coverage centers on administering a therapeutically effective amount of 10(Z)-hexadecenoic acid to treat sepsis and/or prevent or treat post-sepsis syndrome, with dependent claims refining delivery by intravenous injection or by an intratracheal route.
Stated Advantages
Inhibits LPS-stimulated IL-6 secretion from macrophages.
Downregulates proinflammatory cytokine and chemokine mRNA (RNAseq analysis).
Activates PPAR signaling.
Reduces inflammatory cell populations (eosinophils and macrophages) and alters IL-5 and IL-10 in a mouse allergic inflammation model [as described].
Documented Applications
Treating sepsis and/or preventing or treating post-sepsis syndrome (PSS) in a patient in need of such treatment.
Interested in licensing this patent?